This novel approach hinges on the application of machine learning algorithms to decode the brain’s complex electrical activity. Similar to how a linguist learns a new language by identifying patterns and inferring meaning, the algorithm constructs a comprehensive “dictionary” of brain waveforms. By recognizing frequently occurring patterns in EEG data and interpreting them in context, the system unveils nuances that escape even the sharpest human observers. This technology promises to reveal the hidden electrical language of the brain, providing insights into neurological functions and dysfunctions.

The proof-of-concept exploration employed genetic mouse models harboring variations in the TSC1 gene, known to provoke epileptic conditions. Unlike traditional studies that require seizure occurrences during EEG monitoring, this investigation focused purely on “normal” brain activity, capturing data segments free from visible seizure episodes. The algorithm successfully identified subtle, strain-dependent EEG differences that correlated with the presence of the pathogenic gene mutation. This discerning capability demonstrated that neurological alterations manifest in baseline brain activity, even sans overt symptoms.

Notably, the research leveraged a diverse group of over 40 mice, encompassing three distinct genetic strains, which allowed the team to test the algorithm’s robustness across varied biological backgrounds. By analyzing EEG data collected over multiple days, the method demonstrated remarkable accuracy in differentiating seizure-prone mice from their healthy counterparts. These findings illuminate the possibility that epilepsy-related neural networks subtly alter brain rhythms, forming a detectable signature that could revolutionize diagnosis.

The University of Delaware collaborative effort stems from a synergistic partnership between the fields of computational neuroscience and biomedical engineering. Insights from Dr. Austin Brockmeier, an assistant professor specializing in electrical and computer engineering, melded with Dr. Amanda Hernan’s expertise in psychological and brain sciences, focusing on pediatric epilepsy. Their combined approach bridges computational rigor with clinical relevance, targeting tangible improvements in diagnostic precision and patient outcomes.

Looking forward, the research team is poised to translate these technical innovations from murine models to human clinical settings. Supported by funding from the Delaware Clinical and Translational Research ACCEL Program, ongoing studies aim to apply the AI algorithm to pediatric EEG recordings from children undergoing epilepsy evaluation at Nemours Children’s Health. Pediatric EEGs pose additional challenges due to their brevity and the heterogeneity of epilepsy manifestations, but the team remains hopeful that their refined analytical tools will uncover neural biomarkers predictive of disease onset.

A significant virtue of this AI-driven method lies in its capacity to detect brain activity changes long before seizures manifest, potentially enabling preemptive therapeutic interventions. By capturing subtle fluctuations in the brain’s electrical landscape, the system could provide neurologists with a real-time window into disease progression and treatment efficacy, circumventing the current trial-and-error approach. Such early detection would not only hasten diagnosis but also reduce the considerable psychological burden inflicted on families grappling with the uncertainty of epilepsy’s unpredictable cycles.

Beyond diagnosis, the research anticipates broader clinical impacts, including enhanced treatment management. Clinicians frequently face difficulties in assessing medication effectiveness because seizures naturally wax and wane over time. Advanced AI tools capable of continuous EEG pattern recognition could disentangle medication effects from natural seizure-free intervals, guiding data-driven decisions for optimized care.

Further horizons envision wearable EEG technologies integrated with AI analytics, permitting continuous monitoring of high-risk individuals in real-world environments. This real-time vigilance could transform patient care, offering timely alerts and personalized intervention windows. Moreover, analogous machine learning frameworks might be adapted for other complex neurological disorders, including autism spectrum disorders and attention deficit hyperactivity disorder (ADHD), underscoring the versatility and transformative potential of AI in neuroscience.

In essence, this research innovates at the nexus of neuroengineering and precision medicine. Brain-wave typing offers a novel frontier for understanding individualized neural signatures and tailoring interventions that align with each patient’s unique profile. The promise of such advances extends beyond technological novelty, holding the potential to improve lives by delivering clarity, reducing uncertainty, and ultimately guiding more effective treatments in epilepsy and beyond.

The journey from dissecting mouse brain waves to deploying AI-powered clinical diagnostics reflects a powerful example of translational neuroscience. University of Delaware’s interdisciplinary approach showcases how integrating computational algorithms with clinical neuroscience can pave the way for next-generation diagnostic tools. As the technology evolves, it will be critical to ensure robust validation, ethical data use, and seamless integration into healthcare settings to maximize benefit for patients.

Epilepsy’s characteristic unpredictability has long frustrated patients and physicians alike. By transforming the chaotic and complex electrical patterns of the brain into intelligible data, this AI approach offers hope for a future where epilepsy is diagnosed earlier, managed more effectively, and understood more deeply. The implications for reducing the emotional toll on patients and families could be profound, underscoring the vital role of technological innovation in human health.

Subject of Research: Animals

Article Title: Interpretable EEG biomarkers for neurological disease models in mice using bag-of-waves classifiers

News Publication Date: 20-May-2026

Web References:
https://iopscience.iop.org/article/10.1088/1741-2552/ae4d8c

References:
Journal of Neural Engineering, DOI: 10.1088/1741-2552/ae4d8c

Image Credits: Courtesy of The University of Delaware

Keywords: Neurological disorders, Seizures, Epilepsy, EEG, Artificial Intelligence, Machine Learning, Computational Neuroscience, Pediatric Epilepsy, Brain-wave Analysis, Precision Medicine, Biomarkers

Cancer treatment, notorious for its high costs, encompasses far more than just medical expenses. Patients often face additional hardships such as transportation, lodging, and lost income due to missed work, which cumulatively compound financial strain. This multifaceted burden leads to what Dr. Haluk Damgacioglu, Ph.D., lead investigator on the project, refers to as a “complex problem” that can sometimes compel patients to delay or even forgo critical treatments. Recognizing the urgency of this issue, the MUSC research team set out to develop a predictive model that goes beyond conventional clinical risk assessments.

Traditional studies on financial hardship in oncology have largely focused on demographics and retrospective data, leaving a critical gap in predictive care. The tool created by Damgacioglu’s team addresses this by leveraging a rich dataset comprising nearly 800 cancer patients from a national survey. These participants were either undergoing or had recently completed treatment, providing a timely snapshot of financial challenges as they occur. By integrating demographic, clinical, and financial variables into machine learning algorithms, the researchers sought to forecast which patients are most vulnerable to economic strain during their cancer journey.

The technical core of the study involved testing six distinct machine learning models to gauge their ability to predict financial toxicity. Sensitivity—the model’s capacity to accurately identify patients truly at risk—was prioritized to ensure minimal oversight of vulnerable individuals. Ultimately, the researchers fine-tuned their model to achieve an impressive 84% sensitivity and 75% specificity, striking a careful balance between detecting patients who require support and minimizing false positives that could overburden healthcare resources.

Interpretable machine learning methods were employed, offering transparency in a field often criticized for opaque “black box” algorithms. This interpretability enabled identification of the most significant predictors contributing to financial toxicity. Notably, factors such as younger age, lower income, poor general health status, active cancer treatment, and elevated out-of-pocket medical expenses emerged as dominant indicators. Such insights underscore the multifaceted nature of financial risk and provide actionable information for healthcare providers aiming to mitigate patient hardship.

Building on these findings, the research team translated their computational model into a practical clinical tool—a publicly accessible web-based risk calculator. This platform allows clinicians and patients alike to input personalized data and receive a risk classification of low, moderate, or high financial toxicity probability. The tool’s design facilitates early identification and streamlines referrals to specialized financial counseling and support services, a critical step in preventing the cascade of adverse outcomes linked to economic burdens.

At the Hollings Cancer Center, comprehensive patient services include dedicated financial counseling staffed by professionals well-versed in oncology care nuances. Earlier engagement with these resources has the potential to alleviate anxiety surrounding treatment costs, optimize adherence to prescribed regimens, and ultimately improve quality of life for patients. By integrating the risk prediction tool into standard clinical workflows, the hope is to shift the paradigm from reactive to proactive management of financial toxicity.

The implications of this research extend beyond immediate clinical application. Financial toxicity is increasingly recognized as a side effect of cancer, comparable to more traditional physical and emotional sequelae. It bears profound consequences on long-term patient outcomes, including psychological well-being and survival. Future investigations will delve deeper into how financial stress biologically and behaviorally impairs cancer recovery, informing broader strategies that encompass social determinants of health.

The study’s funding by the American Cancer Society and support through the ACS Institutional Research Grant highlights the vital role of institutional backing in advancing innovative healthcare solutions. As machine learning and computational modeling continue to evolve, interdisciplinary collaboration like that demonstrated here is essential for translating data-driven insights into tangible patient benefits. MUSC investigators now plan to validate and refine their model in diverse clinical settings, encompassing varied demographics and cancer types, to enhance generalizability and effectiveness.

In a healthcare landscape increasingly constrained by cost and complexity, leveraging artificial intelligence to address the economic dimensions of cancer care represents a promising frontier. This tool stands as a testament to how technology, coupled with clinical expertise, can empower both providers and patients. By anticipating who will struggle financially, healthcare systems can deploy targeted interventions that maintain treatment continuity and safeguard patient dignity.

Ultimately, this pioneering work underscores the necessity of addressing financial toxicity as an integral component of comprehensive cancer care. As Dr. Damgacioglu aptly states, identifying risk early opens the door to supportive measures that can transform the patient experience. The hope is that such innovations will foster equity and resilience, ensuring that no patient faces the additional burden of financial stress alone during their fight against cancer.

Subject of Research: People
Article Title: Personalized risk prediction of financial toxicity in patients with cancer: An interpretable machine learning study
News Publication Date: 5-May-2026
Web References: Financial Toxicity Risk Calculator
References: JNCI Cancer Spectrum Article DOI: 10.1093/jncics/pkag049
Image Credits: Medical University of South Carolina
Keywords: Cancer treatments, Finance, Stressors

Traditionally, public health has recognized social determinants as pivotal drivers of population health. Factors such as education, socioeconomic status, housing, and employment have shaped research, policy, and intervention strategies for decades. Yet, these models emerged when data collection was limited by low-frequency surveys and health assessments, and when technologies that now mediate much of human interaction and healthcare delivery were nascent at best. The Health Elements framework challenges this traditional approach by recognizing that today’s health outcomes emerge from complex, dynamic interactions that traverse not only the classical domains but also the rapidly evolving technological environment.

The core innovation of the Health Elements framework is its positioning of technology not as an external tool or accessory to healthcare but as a structural force that fundamentally influences health trajectories. Digital infrastructures, AI-driven algorithms, wearable health monitoring devices, and digitally mediated social platforms do more than augment healthcare systems—they reshape behaviors, access, disease detection capabilities, and resource allocation in profound ways. These technologies commingle continuously with biological, behavioral, social, and environmental factors, creating an intricate web of influences that define modern health.

Importantly, the model posits health as an emergent phenomenon, arising from ongoing interactions among five intertwined domains: biological, behavioral, social, environmental, and technological elements. Rather than viewing risk factors as discrete and additive, this framework emphasizes the non-linear, context-dependent nature of health determinants. For instance, identical genetic predispositions may lead to vastly different health outcomes depending on an individual’s social context, environmental exposures, behavioral choices, and, critically, the structure and availability of digital health resources.

The unique role of technology as a cross-domain modifier stands out within the framework. Digital systems do not merely contribute additional data layers; they actively modulate and sometimes amplify interactions among other health determinants. Conversely, the absence or fragmentation of digital infrastructures introduces new vulnerabilities. In low-resource settings, limitations such as fragmented electronic health records, insufficient disease surveillance, and low digital literacy magnify health risks and hinder timely interventions, underscoring digital inequity as a substantive public health issue.

The researchers illustrate their model through an epidemiological case study of chronic kidney disease (CKD) in China. A notable epidemiological shift has occurred in recent decades, with CKD causation moving from primarily glomerular diseases to diabetes-related pathology. This transition cannot be adequately explained by biological trends alone; rather, it reflects simultaneous urbanization, behavioral changes, environmental factors such as pollution, evolving healthcare capacities, and the introduction of digital health infrastructures—including AI-enabled screening and comprehensive electronic health record networks. These digital technologies enable earlier detection and novel management strategies, shaping population health outcomes in real time.

Beyond conceptual advances, the paper explores methodological innovations necessary to study health through the Health Elements lens. The integration of multimodal health data—from genomics and wearable sensors to social media analytics—is critical for capturing the complex interplay of determinants. Computational approaches such as system dynamics modeling, agent-based simulations, and sophisticated causal inference methods hold promise for unraveling causal pathways that span domains and time frames. These tools can help predict health trajectories and guide more effective interventions rooted in an integrated understanding of health ecology.

However, alongside these advances lie pressing ethical and governance challenges. The expansion of data-intensive health systems raises serious concerns about algorithmic bias, privacy infringements, and digital exclusion. If unaddressed, these issues threaten to deepen existing health disparities, especially among marginalized and vulnerable populations who may be underrepresented in digital datasets or lack access to emerging technologies. The researchers emphasize the critical need for transparent data governance frameworks, robust privacy protections, and inclusive design principles to ensure that technologically empowered health systems promote equity rather than entrench inequity.

An editorial accompanying this research in the journal Health Data Science highlights the significance of the Health Elements framework as an essential extension of the longstanding Social Determinants of Health tradition to the digitally mediated contemporary era. Michelle A. Williams, a Professor of Epidemiology and Population Health at Stanford University School of Medicine, notes that this framework provides a promising scientific architecture for understanding how health emerges from complex, interacting systems, moving beyond simplistic linear causal models toward a systems science perspective.

Looking forward, the researchers advocate for longitudinal studies incorporating integrated data streams to validate and refine the Health Elements framework. Strengthening causal inference methodologies and developing multidomain data ecosystems will be crucial for translating this integrated perspective into tangible improvements in disease prediction, preventive interventions, and health equity. As digital technologies continue to evolve and permeate every facet of human life, frameworks like Health Elements will be indispensable for guiding research, policy, and practice in global health.

In sum, the Health Elements framework redefines health as the dynamic product of intersecting biological, behavioral, social, environmental, and technological domains. It underscores the profound and active role of technology as both a driver and modifier of health opportunities and risks in the 21st century. By embracing this integrated vision, researchers and policymakers can better navigate the complexities of contemporary health challenges and harness digital innovations to promote more equitable and effective health systems worldwide.

Subject of Research: Integration of technological determinants with biological, behavioral, social, and environmental factors in health; conceptual advancement in public health models.

Article Title: Digital and AI-Empowered Health Elements: An Integrated Pathway to Advancing Health

News Publication Date: 15-May-2026

Web References: https://dx.doi.org/10.34133/hds.0468

Image Credits: Credit: LUXIA ZHANG

Keywords: Public health, Artificial intelligence, Health equity

The novel device developed by Professor Chi Ming Che, Zhou Guangzhao Professor in Natural Sciences and Chair Professor of Chemistry at HKU, in collaboration with Dr. Wei Liu, represents a paradigm shift in the approach to cancer diagnostics. Bridging synthetic chemistry with cutting-edge artificial intelligence, this portable instrument offers a rapid, straightforward, and user-friendly cancer risk assessment that eschews the need for tissue biopsies or complex laboratory infrastructure. This innovation was recently lauded with the prestigious Gold Medal and Congratulations of the Jury at the 51st International Exhibition of Inventions of Geneva (2026), underscoring its scientific significance and potential to transform public health monitoring on a global scale.

At the heart of this technological marvel lies a unique class of luminescent metal complexes synthesized under Professor Che’s guidance. These metal complexes possess an extraordinary affinity for damaged DNA sites — particularly mismatches — which often serve as molecular hallmarks of oncogenic processes. Unlike conventional dyes or probes, these complexes undergo pronounced changes in their photoluminescent properties upon binding to compromised DNA strands, generating an optical signal of remarkable sensitivity and specificity. This luminescence phenomenon is directly correlated with the extent of DNA damage, allowing for quantitative assessment of cancer-related molecular aberrations without cumbersome sample preparation or specialized labeling.

To capture and interpret these delicate optical signals, the research team developed a miniaturized, high-precision spectrometer engineered by Dr. Wei Liu. This spectrometer operates seamlessly within the handheld device, detecting fluctuations in emission spectra triggered by the DNA-bound luminescent probes. Crucially, the raw spectroscopic data is fed into an advanced artificial intelligence engine that executes sophisticated pattern recognition and machine learning algorithms. This AI component distills complex optical signatures into clinically actionable insights, enhancing both the accuracy and speed of cancer risk prediction. The marriage of molecular sensing with AI-powered analytics heralds a new era where diagnostic precision meets digital efficiency.

Designed with portability and accessibility in mind, the device empowers individuals to conduct self-administered cancer risk screenings using merely a saliva sample, circumventing the discomfort and risks associated with invasive tissue biopsies. The entire detection process unfolds within ten minutes, facilitated via an intuitive mobile application interface that guides users through sample collection, analysis, and interpretation of results. This democratization of cancer screening holds immense promise, particularly for high-risk populations such as individuals with familial cancer histories or patients under continuous post-treatment surveillance, who require frequent and hassle-free monitoring.

Professor Che emphasizes that while this groundbreaking tool is not intended to supplant established clinical diagnostic procedures, it serves as a potent auxiliary platform for rapid detection and longitudinal tracking. Preliminary clinical investigations involving patients diagnosed with breast cancer and nasopharyngeal carcinoma have yielded compelling evidence of the device’s capability to discriminate effectively between patients afflicted by malignancy and healthy individuals. These encouraging findings lay the groundwork for expansive validation efforts, as the HKU research team presently collaborates closely with oncologists from multiple hospitals to assess the technology’s efficacy across a diverse array of cancer types and patient cohorts.

Beyond its clinical applications, the technology exemplifies the power of interdisciplinary innovation — uniting the realms of synthetic chemistry, optical physics, and artificial intelligence into a harmonious diagnostic ecosystem. The luminescent metal complexes, a novel chemical entity crafted through meticulous molecular design, underscore the potential of chemical biology to yield tools that decipher complex biological phenomena at a molecular level. Meanwhile, AI’s capacity to parse multifaceted data patterns in real-time offers unprecedented advantages in translating these molecular events into reliable health indicators.

The societal implications of this development are profound. Cancer imposes staggering costs not only in lives lost but also in economic and social hardships. Early detection and continuous monitoring reduce these burdens by enabling timely interventions that improve prognoses and conserve healthcare resources. By delivering an easily deployable, low-cost, and scalable technology, this device could markedly enhance screening coverage, especially in underserved or resource-limited regions where traditional diagnostic infrastructure is scarce.

Moreover, the technology aligns with broader trends in personalized and precision medicine, where diagnostic tools tailor healthcare responses to individual molecular profiles. Its ability to detect subtle DNA damage signatures non-invasively dovetails with efforts to shift cancer care upstream — focusing on prevention, early interception, and personalized risk stratification. As the device integrates seamlessly with digital health platforms, it can potentially interface with telemedicine services, further extending its reach and impact.

In essence, this AI-integrated optical sensing device not only embodies a leap forward in cancer diagnostics but also illustrates a compelling blueprint for the next generation of biomedical innovations: compact, intelligent, and patient-centric technologies designed to empower individuals and enhance public health outcomes. The convergence of chemical ingenuity and artificial intelligence opens new vistas for detecting and understanding disease processes in ways previously unattainable, bringing us closer to a future where cancer detection is swift, safe, and universally accessible.

The University of Hong Kong and the Laboratory for Synthetic Chemistry and Chemical Biology Limited (LSCCB) continue to spearhead this ambitious initiative, striving to translate laboratory breakthroughs into tangible clinical benefits. Their ongoing collaborations with medical practitioners and commitment to rigorous validation promise to refine and optimize this technology for broader clinical deployment. With further development and integration, this innovative device could become an indispensable tool in the global fight against cancer, exemplifying how scientific excellence can be harnessed to achieve meaningful societal impact.

For inquiries related to this pioneering research, contact the Office of Vice-President and Pro-Vice-Chancellor (Research) at The University of Hong Kong, or Ms. Esther YIU via telephone or email.

Subject of Research: Development of a portable AI-enabled optical sensing device for rapid, non-invasive cancer risk detection using saliva samples.

Article Title: AI-Powered Optical Device Enables Rapid, Non-Invasive Cancer Risk Screening via Saliva Analysis

News Publication Date: Not specified

Web References: Not specified

References: Not specified

Image Credits: The University of Hong Kong

Keywords: Cancer detection, non-invasive diagnostics, optical sensing, luminescent metal complexes, artificial intelligence, saliva-based screening, biosensors, molecular diagnostics, digital health, early cancer screening

The investigation centered on whether an LLM could navigate the intricacies of reviewing real, unfiltered patient charts—often fraught with incomplete, inconsistent, or ambiguous data—and effectively synthesize the information to arrive at accurate diagnoses and recommend appropriate next steps. Unlike many prior studies that rely on sanitized or idealized datasets, this research embraced the inherent complexity and “messiness” of live electronic health records (EHRs), thereby reflecting authentic clinical environments and offering a robust assessment of AI’s practical performance.

Employing evaluation benchmarks rooted in long-established standards for assessing physician competence—some dating back to methodologies developed in the 1950s—the researchers subjected the model to rigorous diagnostic challenges, clinical reasoning exercises, and real-time emergency department case analyses. The LLM was tested continuously at various critical junctures of patient care, from initial triage when data are sparse to admission decisions informed by more comprehensive clinical findings.

Remarkably, the AI model not only matched but often surpassed the diagnostic accuracy of experienced attending physicians during these early decision points. This finding was particularly striking given the traditionally unpredictable and data-scarce nature of early emergency assessments. Researchers noted that the model’s ability to operate under these conditions signaled a transformative shift in AI’s readiness to contribute meaningfully to frontline medical decision-making.

Co-senior author Arjun (Raj) Manrai, assistant professor of biomedical informatics at Harvard Medical School, emphasized that while the AI model eclipsed previous iterations and physician baselines across multiple clinical tasks, this accomplishment does not imply that autonomous AI-driven medical practice is imminent. Instead, he underscored the importance of conducting rigorous prospective clinical trials to systematically evaluate the impact and safety of integrating AI tools in diverse care settings before widespread adoption.

Peter Brodeur, MD, MA, a co-first author and clinical researcher at BIDMC, highlighted a significant implication of these findings for the future of AI evaluation metrics. Traditional assessment methodologies, such as multiple-choice tests long used to gauge medical knowledge, no longer offer sufficient resolution to differentiate the rapidly advancing capabilities of modern AI systems, which are now routinely achieving near-perfect scores. This ceiling effect necessitates innovative, contextually rich benchmarks that mirror the nuanced realities of clinical practice.

Furthermore, the study’s design preserved the authenticity of emergency department workflows by presenting the LLM with clinical data precisely as recorded in the EHR, unprocessed and unfiltered. Adam Rodman, MD, MPH, hospitalist and co-senior author, noted the deliberate avoidance of data smoothing techniques common in many AI trials, thereby challenging the model to contend with the full breadth of real-world clinical variability and imperfections.

Despite the model’s promising performance, the researchers maintain a cautious stance regarding its clinical deployment. They acknowledge that although the AI may frequently propose the correct leading diagnosis, it might also recommend additional tests or interventions that are unnecessary or potentially harmful, underscoring that human clinicians must remain integral to the diagnostic workflow to ensure patient safety and care quality.

Thomas Buckley, a doctoral student at Harvard’s AI in Medicine PhD program and co-first author of the study, emphasized the significance of assessing AI’s capabilities early in the diagnostic trajectory, when patient information is limited. This approach more accurately reflects real-world decision-making processes and challenges, challenging the AI to demonstrate proficiency in ambiguous and evolving clinical scenarios rather than well-defined, retrospective cases.

Collectively, these results herald a pivotal moment in the field of medical artificial intelligence. Rather than viewing these systems’ promising diagnostic accuracy as endpoints, the authors advocate for their evaluation through the lens of medical science’s gold standard: controlled clinical trials in authentic healthcare environments. This approach will elucidate the true benefits, limitations, and safety considerations inherent in adopting AI-assisted clinical practice.

The institutions spearheading this research—Harvard Medical School and Beth Israel Deaconess Medical Center—are renowned for their leadership in medical innovation, education, and research. Their combined expertise has facilitated a landmark study that not only challenges previous assumptions about AI’s clinical abilities but also sets a new benchmark for future investigations exploring how artificial intelligence can augment human judgment in medicine.

Looking ahead, the study propels the conversation about AI’s role in healthcare beyond theoretical performance metrics into practical, patient-centered applications. It underscores the pressing need for interdisciplinary collaboration among technologists, clinicians, ethicists, and policymakers to navigate the complex landscape of AI integration responsibly and effectively.

In sum, this research redefines expectations for large language models in clinical environments, proving that AI systems are now capable of reasoning and decision-making at a level that rivals seasoned physicians, particularly in the fast-paced and unpredictable context of emergency medicine. However, it equally stresses that the path forward requires prudence, comprehensive validation, and a reaffirmation of the indispensable role of human expertise in ensuring patient welfare.

Subject of Research: Not applicable

Article Title: Performance of a large language model on the reasoning tasks of a physician

News Publication Date: 30-Apr-2026

Web References: 10.1126/science.adz4433

Keywords

AI common sense knowledge, Computer science, Machine learning, Clinical medicine

A groundbreaking study from Duke Health harnesses the power of AI to analyze routine electronic health records (EHRs) and estimate the risk of ADHD well before conventional clinical diagnosis occurs. The study, published in Nature Mental Health, dives deep into the wealth of clinical data accumulated in primary care settings. Researchers developed a sophisticated AI model trained on EHR data from more than 140,000 children, effectively unlocking hidden patterns across developmental, behavioral, and clinical parameters from birth through early childhood.

This AI-based predictive model is not a diagnostic instrument per se but functions as a risk stratification tool. It sifts through vast repositories of medical histories, identifying subtle, intricate interplays of variables that often presage an eventual ADHD diagnosis. Importantly, the model exhibits high predictive accuracy from the age of five onwards, maintaining robust performance across diverse demographics including sex, race, ethnicity, and insurance status. This generalizability marks a significant advance over previous attempts that often struggled with bias or limited datasets.

The transformative potential of such an AI-driven approach lies in its capacity to propel ADHD assessment into a proactive phase rather than reactive recognition. Typically, children with ADHD are diagnosed only after years of behavioral challenges and academic struggles. Early risk estimation equips pediatricians and primary care providers with actionable alerts, empowering them to closely monitor at-risk children and initiate timely referrals for comprehensive diagnostic evaluations by specialists.

Elliot Hill, the study’s lead author and a data scientist at Duke’s Department of Biostatistics & Bioinformatics, emphasizes the untapped richness of electronic health records. The AI effectively distills complex clinical narratives into predictive insights, demonstrating that everyday medical data can yield powerful prognostic signals that were previously inaccessible. Rather than creating an AI “doctor,” the model serves as an assistive technology aimed at optimizing clinician workflow and resource allocation.

Matthew Engelhard, M.D., Ph.D., the study’s senior author, underscores that automated tools like this could prevent many children from “falling through the cracks.” By spotlighting those who are at heightened risk, clinicians can allocate more focused attention and deploy evidence-based interventions sooner, which is strongly correlated with enhanced academic and psychosocial outcomes.

From a technical perspective, the AI model employs advanced machine learning techniques capable of integrating vast multidimensional data points, including developmental milestones, recorded behavioral issues, comorbid medical conditions, and even patterns indicating healthcare utilization. This holistic analysis leverages longitudinal data, allowing the system to discern trajectories rather than relying on static snapshots, which greatly enhances prediction accuracy.

Despite these promising results, the researchers caution that the AI tool requires further validation before widespread clinical adoption. Rigorous prospective studies and real-world trials are necessary to assess effectiveness, safety, and ethical implications. Additionally, integration within existing healthcare infrastructures presents logistical challenges, including data standardization, patient privacy considerations, and interoperability with diverse EHR systems.

Naomi Davis, Ph.D., an associate professor in the Department of Psychiatry and Behavioral Sciences and co-author, highlights the critical importance of connecting at-risk families with timely, evidence-based supports. Early identification must be paired with adequate resources and interventions tailored to each child’s unique needs, or else the benefits of predictive technology risk being lost.

This research aligns with a larger movement harnessing AI to predict and understand mental health risks across the lifespan. Hill and Engelhard have contributed additional studies exploring AI applications in adolescent mental illness, illustrating a growing commitment to integrating computational models into psychiatric epidemiology and personalized medicine.

The study benefits from robust funding by the National Institute of Mental Health and the National Center for Advancing Translational Sciences, signaling strong institutional support for leveraging AI as a transformative force in medical diagnostics. As the field continues to innovate, such AI-driven models may soon be integral to pediatric care, enabling clinicians to anticipate disorders like ADHD with unprecedented precision and intervene at life-changing early stages.

In summary, this pioneering work demonstrates that AI tools analyzing routine clinical data can efficiently predict ADHD risk long before traditional diagnoses arise. By embedding such technologies into everyday healthcare workflows, there is a distinct possibility of drastically transforming outcomes and quality of life for millions of children worldwide, delivering on the promise of precision medicine tailored from the very start of life.

Subject of Research: Early prediction of attention-deficit/hyperactivity disorder (ADHD) risk in children through artificial intelligence analysis of electronic health records

Article Title: Artificial Intelligence Models Predict Childhood ADHD Risk Years Before Diagnosis Using Routine Electronic Health Records

News Publication Date: April 27, 2026

Web References: https://www.nature.com/articles/s44220-026-00628-2

Image Credits: Duke Health / Shawn Rocco

Keywords

Attention-deficit/hyperactivity disorder, ADHD, artificial intelligence, AI, electronic health records, EHR, pediatric medicine, early diagnosis, machine learning, neurodevelopmental disorders, predictive modeling, mental health

The study explicitly explores the correlation between the deployment of AI algorithms and the enhancement of consumer diagnostic accuracy. Previous paradigms relied heavily on direct clinician-patient interactions or rudimentary online resources, but the advent of sophisticated AI algorithms presents novel avenues. These systems leverage complex neural networks trained on vast dermatological datasets to identify skin conditions with precision. The research underscores that accuracy improvements were directly linked to the reliability of the AI-generated predictions, reinforcing that the fidelity of AI outputs is paramount in fostering better clinical outcomes for end-users.

Moreover, the investigation delves deeply into the psychological impact of AI diagnostic aids on user confidence. Confidence here is critical as it influences healthcare-seeking behaviors and compliance with recommended treatments. Results revealed that users exposed to AI-supported diagnostic predictions exhibited significantly elevated confidence levels in their understanding of their skin conditions. This finding posits that AI integration could empower consumers by converting uncertainty into actionable knowledge, thereby promoting earlier intervention and improved disease management.

However, the study also uncovers substantial challenges, particularly when AI predictions do not perfectly align with dermatologists’ differential diagnoses. Such “imperfect guessing accuracy” can lead to consumer confusion or misinterpretation, highlighting an urgent need for refined design elements within AI applications. The ambiguity introduced by discrepancies between AI output and expert opinion accentuates the necessity for transparent communication pathways and educational components within these digital tools to ensure users correctly interpret and contextualize the diagnostic information presented.

Importantly, the researchers emphasize that the benefits of AI are maximized only when the diagnostic predictions approach a high degree of accuracy. In other words, while AI holds immense promise, suboptimal algorithmic performance may inadvertently erode user trust or lead to diagnostic errors. This caveat alerts developers and clinicians alike that ongoing refinement in AI model training, validation, and deployment is essential to fully harness AI’s advantages in dermatology.

The implications of these findings stretch far beyond cosmetic or trivial skin concerns; accurate consumer understanding of dermatological conditions can fundamentally alter public health trajectories, particularly for chronic or potentially severe skin disorders. Enhanced AI tools could facilitate earlier detection of conditions such as melanoma, psoriasis, or eczema, catalyzing timely medical intervention and potentially reducing morbidity and healthcare costs.

Technically, the AI models evaluated in this study are typically constructed using deep convolutional neural networks (CNNs), which excel at image-based classifications. These models are trained on millions of annotated dermatoscopic images, enabling them to discern subtle visual patterns that may escape the untrained eye. Their capacity to replicate, and in some cases exceed, dermatologist-level diagnostic accuracy underscores AI’s unprecedented role in skin disease diagnostics.

Nevertheless, the study’s authors caution that while AI’s image recognition prowess is formidable, diagnostic accuracy is equally dependent on the contextual framing of information shared with the consumer. The presentation of condition explanations, possible prognoses, and recommended next steps must be carefully crafted to mitigate misunderstandings. Thus, the study advocates for an interdisciplinary approach that merges technical AI development with behavioral science and health communication strategies to optimize consumer outcomes.

Furthermore, the research identifies key areas where AI diagnostic platforms can evolve, such as integrating multimodal data — combining images with patient history, symptoms, and possibly genetic data — to elevate the precision of predictions. By broadening the data inputs, AI can mimic the holistic diagnostic approach clinicians employ, moving beyond static image analysis toward dynamic, personalized diagnostic tools.

This study also reinforces the ethical considerations intrinsic to AI in medical practice. With imperfect predictions potentially misleading users, the responsibility falls on developers and regulatory bodies to ensure stringent validation and transparent reporting of AI capabilities and limitations. Ethical deployment must safeguard against overreliance on technology, ensuring that AI serves as an adjunct to, rather than a replacement for, professional medical evaluation.

In conclusion, the study positions AI as a powerful agent of change in dermatology, capable of elevating consumer understanding, diagnostic accuracy, and health outcomes if deployed thoughtfully. The path forward lies in continual algorithmic refinement, enhanced user interface designs, and comprehensive educational frameworks. Collectively, these advancements will empower consumers and clinicians alike, fostering a new paradigm of accessible, precise, and user-friendly dermatological care.

Corresponding author Rory Sayres, PhD, emphasizes the ongoing collaboration between AI researchers and dermatology specialists as vital to overcoming current limitations. Future research is anticipated to focus on large-scale real-world implementation studies, assessing AI effectiveness across diverse populations and conditions. As AI continues to evolve, the integration of these technologies promises a future where skin health management is more proactive, personalized, and democratized than ever before.

This study opens exciting avenues not only within dermatology but across the broader landscape of medical diagnostics. Harnessing AI’s full potential in consumer health applications will likely redefine patient engagement, disease management, and clinical workflows across medical specialties, heralding a new era of AI-empowered healthcare.

Subject of Research: The study investigates the application of artificial intelligence in improving consumer understanding, confidence, and diagnostic accuracy related to skin conditions.

Article Title: Not specified in the provided content.

News Publication Date: Not specified in the provided content.

Web References: Not available in the provided content.

References: (doi:10.1001/jamadermatol.2026.0597)

Image Credits: Not provided.

Keywords

Skin, Artificial Intelligence, Skin Disorders, Medical Diagnosis, Dermatology

The comprehensive study surveyed over 5,500 adults across the United States during the last quarter of 2025, yielding robust, nationally representative data that delve into the motivations behind AI health tool usage. Among users in the last 30 days, speed emerges as a primary driver—71% sought rapid answers to their health queries. The same percentage cited a desire for supplementary information, illustrating how AI fulfills a critical role in augmenting patient understanding. Notably, 67% expressed curiosity about AI responses, signaling a broader societal intrigue regarding machine-generated healthcare insights.

The AI-driven exploration often occurs both pre- and post-consultation, with 59% of users employing AI tools for research prior to medical appointments and 56% engaging with these technologies after seeing a provider. Such usage patterns underscore the growing trend of self-directed healthcare research, facilitated by the instantaneous accessibility that AI systems provide. This dynamic challenges traditional healthcare workflows, inviting providers to consider integrated approaches that recognize AI as a partner in patient education and engagement.

Beyond convenience, AI adoption in healthcare is influenced by systemic barriers. Approximately 27% of users turned to AI to circumvent costs associated with doctor visits, while 14% utilized these tools due to an inability to afford professional consultations. Accessibility constraints also propel AI use; 21% lacked the time to schedule appointments, and 16% faced difficulties in obtaining provider access. Furthermore, 42% sought AI assistance outside regular business hours, highlighting the technology’s potential to bridge gaps in healthcare availability beyond conventional scheduling frameworks.

Psychosocial factors contribute significantly to AI’s appeal. About 21% of users reported feeling dismissed or ignored by healthcare providers previously, and 18% found engaging with a human provider intimidating or embarrassing. These insights reflect the role of AI as a stigma-reducing intermediary, offering a non-judgmental and anonymous avenue for health inquiry. Such findings raise critical questions about the patient-provider relationship and suggest avenues for improving human-centered care through complementary AI solutions.

Financial disparities manifest strongly in AI healthcare use patterns. Data reveals a steep income gradient in turning to AI due to cost barriers; 32% of adults earning less than $24,000 annually reported using AI for this reason, compared to only 2% among those with incomes exceeding $180,000. This divide underscores how AI might function as an equalizer, offering a low-cost alternative or supplement for underserved populations, though not without concerns regarding quality and trustworthiness.

Despite the burgeoning reliance on AI, trust in AI-generated health information remains evenly split. One-third of users express trust, one-third harbor skepticism, and the remaining third are ambivalent. Crucially, only a mere 4% strongly trust the accuracy of AI outputs. This hesitancy reveals underlying uncertainties about the reliability and veracity of machine-delivered health advice, emphasizing the need for transparent validation mechanisms and user education to foster informed engagement.

Moreover, 11% of users who engaged with AI health advice during the survey period reported receiving recommendations they deemed unsafe. This alarming finding highlights the potential risks inherent in unregulated or inadequately supervised AI health tools. It surfaces the pressing imperative for stringent oversight, evidence-based algorithm design, and integration with professional healthcare frameworks to mitigate adverse outcomes.

Applications of AI in healthcare extend beyond primary symptom evaluation. Many users deploy these tools to interpret medication side effects, clarify complex medical data, and investigate diagnoses and chronic conditions. For instance, 59% of AI health users sought information related to nutrition or exercise, while 38% researched diseases or medical diagnoses, and 24% explored mental health issues. This breadth demonstrates AI’s expanding footprint across various domains of health management.

Age influences AI health engagement significantly. Younger adults aged 18 to 29 demonstrate more frequent pre-appointment research behaviors (69%) compared to seniors aged 65 and older (43%). This generational gap reflects broader digital literacy trends and comfort with emerging technologies. It suggests that AI dissemination strategies and user interfaces may need tailoring to enhance accessibility and effectiveness across diverse age cohorts.

Interestingly, while 84% of recent AI health users also saw a healthcare provider, 14% chose not to visit a doctor they otherwise would have, based on AI advice. Extrapolated to the national population, this equates to roughly 14 million adults potentially substituting professional consultation with AI-generated guidance. Such behavioral shifts necessitate a critical evaluation of AI’s role in healthcare decision-making and its implications for patient outcomes and healthcare system burdens.

This comprehensive investigation not only illuminates the evolving terrain of AI in healthcare information-seeking but also challenges stakeholders—providers, policymakers, and developers—to adapt proactively. As Tim Lash, President of West Health Policy Center, articulates, the velocity of AI adoption exceeds the pace at which health systems are preparing to responsibly harness and govern this technology. The balance between innovation and caution will shape the future of AI’s symbiotic relationship with healthcare delivery.

In conclusion, the West Health-Gallup study underscores artificial intelligence’s transformative potential as both a complement and, occasionally, a substitute for traditional healthcare engagement. While the rapid accessibility and breadth of AI-provided information empower patients in unprecedented ways, concerns around trust, safety, cost, and access accentuate the need for thoughtful integration. The ongoing dialogue around AI in healthcare must prioritize patient-centric frameworks, ensuring these powerful tools augment rather than compromise the quality and equity of care.

Subject of Research: Use of Artificial Intelligence Tools and Chatbots for Physical and Mental Healthcare Information and Advice Among U.S. Adults

Article Title: U.S. Adults Increasingly Turn to AI for Healthcare Guidance: Balancing Convenience with Caution

News Publication Date: April 15, 2026

Web References:

• West Health-Gallup Center on Healthcare in America: https://westhealth.gallup.com/
• West Health: https://www.westhealth.org/

Keywords: artificial intelligence, AI healthcare, chatbot, healthcare information, patient engagement, health disparities, healthcare access, medical cost barriers, digital health, AI trust, healthcare technology, health equity

Heart disease diagnosis has historically relied on a combination of clinical judgment, patient history, and standard diagnostic tests such as electrocardiograms, echocardiograms, and blood work. However, the complex multifactorial nature of heart disease complicates straightforward prediction, as it involves numerous interrelated risk factors with varying degrees of influence. Traditional predictive models often struggle with balancing these factors and handling inherent uncertainties in clinical data, leading to false positives or negatives that can have serious implications.

The new framework presented by Wang, Fan, Yu, and colleagues addresses these limitations head-on by embedding uncertainty quantification directly into the feature weighting mechanism within an ensemble model structure. Ensemble models combine predictions from multiple algorithms to improve overall performance, but not all features contribute equally, and not all features’ contributions are certain. By incorporating an uncertainty-aware approach, the system dynamically adjusts the weighting of features based on the confidence level in the data, refining prediction accuracy.

This research leverages a combination of advanced machine learning techniques and probabilistic modeling. The ensemble framework integrates multiple base learners, each trained on different subsets of the data and features, ensuring diverse perspectives on the prediction task. Importantly, the model estimates uncertainty for each feature’s contribution by evaluating variability and noise within the input data, an approach inspired by Bayesian principles but optimized for practical large-scale clinical datasets.

The implication of this methodology is profound. In real-world clinical scenarios, data can be incomplete, noisy, or inconsistent, and patient heterogeneity further complicates matters. An uncertainty-aware predictive framework explicitly acknowledges these imperfections, allowing clinicians to interpret predictions with a calibrated understanding of confidence intervals rather than absolute binaries. This represents a critical advance toward responsible AI deployment in medicine, where risk and uncertainty must be transparently communicated.

To validate their framework, the researchers utilized comprehensive cardiovascular datasets encompassing diverse patient demographics, clinical histories, lab results, and imaging findings. The model was rigorously compared against standard machine learning classifiers widely used in this domain. Results demonstrated not only superior predictive performance but also enhanced robustness against overfitting and sensitivity to data anomalies, underlining the practical viability of the approach.

Beyond accuracy, the ensemble’s feature weighting provides valuable insights into the relative importance of various risk factors for individual patients. This personalized risk profiling can assist physicians in tailoring preventive interventions or treatment plans. The interpretability of the model’s outputs—in terms of which features most influenced the risk estimate—addresses a key concern in clinical AI applications: explainability.

Furthermore, the framework’s scalable architecture enables easy adaptation and retraining as new clinical data becomes available or as heart disease pathophysiology understanding evolves. This adaptability is crucial for maintaining model relevance in a rapidly changing medical environment and for harnessing continuous learning from new patient cohorts or emerging diagnostic modalities.

The study’s authors emphasize that integrating uncertainty quantification in predictive modeling is not only a technical exercise but also an ethical imperative. Misdiagnosis or missed disease detection carries significant consequences, and delivering risk predictions with quantified uncertainty aids clinicians in decision-making under ambiguity. This can translate into better patient outcomes, more efficient resource allocation, and ultimately decreased healthcare costs.

One of the innovative aspects of this framework is its potential applicability beyond heart disease. The underlying principles of uncertainty-aware feature weighting can be transferred to other complex conditions where multifactorial interactions and imperfect data are the norm, such as cancer diagnostics, neurological disorders, or metabolic syndromes. Thus, this work may catalyze a broader paradigm shift in clinical AI.

Critics of AI in healthcare often highlight the “black box” nature of many predictive algorithms, causing mistrust among practitioners and patients alike. The proposed ensemble framework counters this by explicitly modeling uncertainty and clarifying feature contributions, fostering transparency. This transparent risk stratification aligns with contemporary moves towards patient-centric AI, where understanding model rationale enhances acceptance and adherence.

Moreover, the authors discuss integration pathways with existing electronic health record (EHR) systems, suggesting practical deployment in clinical settings without major disruptions. Their modular design ensures seamless interfacing with hospital data infrastructures and real-time updating, enabling continuous decision support during patient consultations.

While this framework marks a substantial advance, the researchers acknowledge several avenues for further refinement. Incorporating longitudinal data to capture disease progression, integrating genomic or proteomic biomarkers, and enhancing interpretative visualizations remain promising directions. Additionally, prospective clinical trials will be essential to evaluate the model’s impact on patient management and outcomes in real-world settings.

The significance of this study extends to public health initiatives as well. Improved prediction tools empower earlier identification of high-risk individuals, facilitating timely interventions that can reduce heart disease incidence on a population scale. By embedding uncertainty awareness, public health policies can incorporate more nuanced risk thresholds, optimizing preventive strategies.

In conclusion, the uncertainty-aware feature-weighted ensemble framework devised by Wang and colleagues represents a landmark evolution in heart disease prediction technologies. By marrying robust machine learning architectures with probabilistic reasoning, this framework not only enhances predictive accuracy but also fosters transparency and ethical responsibility in AI-driven healthcare. As cardiology continues to embrace digital innovation, such advances herald a new era of precision medicine that is both data-driven and human-centered.

Subject of Research: Heart disease prediction using advanced machine learning frameworks.

Article Title: Uncertainty-aware feature-weighted ensemble framework for heart disease prediction.

Article References:
Wang, X., Fan, Y., Yu, M. et al. Uncertainty-aware feature-weighted ensemble framework for heart disease prediction. Sci Rep (2026). https://doi.org/10.1038/s41598-026-42419-w

Image Credits: AI Generated

Insulin resistance—a metabolic condition in which the body’s tissues fail to respond adequately to insulin—is a principal driving factor behind type 2 diabetes. The clinical implications of insulin resistance extend far beyond diabetes alone; it has long been associated with cardiovascular, renal, and hepatic diseases. However, quantitatively evaluating insulin resistance in a clinical setting remains a formidable challenge due to the complexity and invasiveness of direct measurement techniques. This limitation has historically obscured the broader epidemiological relationship between insulin resistance and various cancers.

The study led by Yuta Hiraike and collaborators addresses this knowledge gap through the development of AI-IR, an artificial intelligence-powered tool that integrates nine different biochemical and clinical markers routinely measured during health checkups. This multi-parametric approach allows AI-IR to generate a reliable insulin resistance score without recourse to complicated or costly assays. The model was rigorously trained and validated using anonymized medical datasets from independent cohorts in the United States and Taiwan, encompassing well over half a million individuals, ensuring robustness and generalizability across diverse populations.

Critically, AI-IR outperforms BMI, a conventional surrogate marker widely used to estimate metabolic risk, by reducing false positives and false negatives in predicting insulin resistance. BMI’s limitations stem from its inability to discriminate between metabolically healthy obese individuals and those with normal weight yet metabolically unhealthy profiles. By synthesizing diverse clinical data points into a single predictive metric, AI-IR offers a more nuanced and precise assessment that captures hidden insulin resistance which BMI alone cannot reveal.

Leveraging UK Biobank data, AI-IR enabled the researchers to conduct one of the largest population-scale analyses ever performed on the relationship between insulin resistance and cancer susceptibility. Their meta-analysis conclusively demonstrated that individuals predicted by AI-IR to have insulin resistance face significantly elevated risks for twelve distinct cancer types. This scale and rigor mark a pivotal milestone—providing the first definitive large-scale evidence that insulin resistance is not merely a correlative but a meaningful risk factor for a broad spectrum of malignancies.

Understanding the biological underpinnings of this link between insulin resistance and cancer implicates chronic hyperinsulinemia and systemic inflammation as potential mechanistic pathways. Insulin resistance results in elevated circulating insulin levels which, aside from regulating glucose metabolism, can function as a mitogen promoting cellular proliferation in various tissues. Additionally, the pro-inflammatory milieu found in insulin-resistant states fosters an environment conducive to oncogenesis, thereby elevating cancer risks.

One of the compelling aspects of this research is its translational potential for preventive medicine. Because AI-IR relies on parameters commonly included in routine health screenings, its implementation can be seamlessly integrated into existing healthcare infrastructures. Identifying individuals with subclinical insulin resistance enables targeted surveillance and early interventions, such as lifestyle modifications or pharmacological treatments, aiming to mitigate the downstream risks of diabetes, cardiovascular disease, and notably, cancer.

The development process of AI-IR also confronted skepticism within the scientific community, particularly around its ability to replicate the predictive accuracy of direct insulin resistance measurements which are impractical at scale. Yet, AI-IR demonstrated consistently strong performance across multiple independent validation datasets, underscoring its viability as an alternative evaluative tool for clinical and epidemiological applications worldwide.

Moreover, the team is actively expanding their research to dissect the genetic determinants that influence individual susceptibility to insulin resistance and related cancer risks. By integrating large-scale genomic data with molecular biology insights, the researchers aim to unravel personalized risk profiles and therapeutic targets, propelling the field toward precision medicine strategies designed to combat these interconnected diseases more effectively.

This study’s implications also reverberate through public health domains, highlighting the necessity for comprehensive metabolic health assessments beyond BMI-centric paradigms. With obesity rates climbing globally and cancer incidence continuing to grow, AI-based innovations like AI-IR may become critical pillars in early detection frameworks, optimizing healthcare resource allocation and improving patient prognoses through preemptive action.

In summary, the introduction of AI-IR epitomizes the transformative power of artificial intelligence in medical research, bridging the gap between complex metabolic phenotypes and disease outcomes. It offers a scalable, accessible, and scientifically rigorous approach to identifying insulin resistance, illuminating its multifaceted role in carcinogenesis and heralding a new era of integrated disease risk prediction that could significantly affect cancer epidemiology and prevention strategies worldwide.

Subject of Research: People

Article Title: Machine learning-predicted insulin resistance is a risk factor for 12 types of cancer

News Publication Date: 16-Feb-2026

Web References:
https://doi.org/10.1038/s41467-026-68355-x

References:
Chia-Lin Lee, Tomohide Yamada, Wei-Ju Liu, Kazuo Hara, Toshimasa Yamauchi, Shintaro Yanagimoto & Yuta Hiraike, “Machine learning-predicted insulin resistance is a risk factor for 12 types of cancer”, Nature Communications

Image Credits:
©2026 Hiraike et al. CC-BY-ND

Keywords:
Insulin resistance, AI-IR, machine learning, cancer risk, diabetes, metabolic health, BMI, artificial intelligence, epidemiology, predictive modeling, population health, precision medicine